Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220021/S006

DETOUR System

Endologix, LLC · Decision date Oct 9, 2025

FDA DECISIONP220021/S006

What did the FDA approve?

FDA records P220021/S006 as a supplement to PMA P220021, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Oct 9, 2025.

FDA approval order statement

a manufacturing site located at Endologix, LLC at 3910 Brickway Blvd., Santa Rosa, CA 95403 for manufacturing the TORUS Stent Graft System and associated manufacturing changes and for an alternate contract sterilizer for the TORUS Stent Graft System located at Steris Isomedix Services at 43425 Business Park Drive, Temecula, CA 92590
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Oct 9, 2025
FDA change category
Location Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P220021/S006
Regulatory pathway
PMA supplement
Product code
QWM
Decision code
APPR
Decision date
Oct 9, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stent graft, bypass, superficial femoral artery.

Product code
QWM
FDA device class
3

For the original device and its historical approval scope, see PMA P220021. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P220021/S006 received

    Application receipt date recorded by FDA.

  2. P220021/S006 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P220021. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220021

Product / regulatory recordCompanyPathwayDecision dateSource
Endologix, LLCPMA approvalJun 7, 2023FDA
DETOUR SystemP220021/S005
Endologix, LLCPMA supplementSep 18, 2025FDA
DETOUR SystemP220021/S008
Endologix, LLCPMA supplementDec 23, 2025FDA
DETOUR SystemP220021/S007
Endologix, LLCPMA supplementJan 22, 2026FDA
DETOUR SystemP220021/S009
Endologix, LLCPMA supplementOct 16, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Endologix, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3910 Brickway Blvd., Santa Rosa, CA, 95403

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records